E
7.05
0.08 (1.15%)
Penutupan Terdahulu | 6.97 |
Buka | 6.97 |
Jumlah Dagangan | 227,318 |
Purata Dagangan (3B) | 246,181 |
Modal Pasaran | 154,117,232 |
Harga / Jualan (P/S) | 3.20 |
Harga / Buku (P/B) | 10.31 |
Julat 52 Minggu | |
Tarikh Pendapatan | 4 Aug 2025 |
Margin Keuntungan | -27.34% |
Margin Operasi (TTM) | -21.71% |
EPS Cair (TTM) | -0.840 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 7.50% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 367.92% |
Nisbah Semasa (MRQ) | 2.32 |
Aliran Tunai Operasi (OCF TTM) | -14.91 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.11 M |
Pulangan Atas Aset (ROA TTM) | -19.21% |
Pulangan Atas Ekuiti (ROE TTM) | -117.50% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
Diagnostics & Research (Global) | Bercampur | Bercampur | |
Stok | Exagen Inc. | Menaik | Menaik |
AISkor Stockmoo
1.9
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | 4.0 |
Purata | 1.88 |
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. |
|
Sektor | Healthcare |
Industri | Diagnostics & Research |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 19.82% |
% Dimiliki oleh Institusi | 45.44% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 17.00 (Keybanc, 141.14%) | Beli |
Median | 12.00 (70.21%) | |
Rendah | 11.00 (Canaccord Genuity, 56.03%) | Beli |
Purata | 13.33 (89.08%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 8.19 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Canaccord Genuity | 30 Jul 2025 | 11.00 (56.03%) | Beli | 8.63 |
Keybanc | 30 Jul 2025 | 17.00 (141.13%) | Beli | 8.63 |
Craig-Hallum | 23 Jul 2025 | 12.00 (70.21%) | Beli | 7.32 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
06 Aug 2025 | Pengumuman | Exagen Inc. to Participate in Third Quarter Investor Conferences |
29 Jul 2025 | Pengumuman | Exagen Inc. Reports Strong Q2 2025 Results |
17 Jul 2025 | Pengumuman | Exagen Inc. Appoints Chas McKhann to Board of Directors |
15 Jul 2025 | Pengumuman | Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 |
23 Jun 2025 | Pengumuman | Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |